Antisense-protein kinase A: A single-gene-based therapeutic approach

Antisense and Nucleic Acid Drug Development

Volumn 7, Issue 3, 1997, Pages 217-223

  Cho Chung, Yoon S ^a   Nesterova, Maria ^a   Kondrashin, Andrey ^a   Noguchi, Kohei ^a   Srivastava, Rakesh ^a   Pepe, Stefano ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; CYCLIC AMP DEPENDENT PROTEIN KINASE; MESSENGER RNA;

APOPTOSIS; CANCER INHIBITION; CELL CYCLE; CELL DIFFERENTIATION; CELL GROWTH; CONFERENCE PAPER; ENZYME INHIBITION; ENZYME SUBUNIT; GENE THERAPY; INTRAPERITONEAL DRUG ADMINISTRATION; LEUKEMIA CELL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

EID: 0030860337     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.1.1997.7.217     Document Type: Conference Paper

References (5)

1. BEEBE, S.J., and CORBIN, J.D. (1986). Cyclic nucleotide-dependent protein kinases. In: The Enzymes: Control by Phosphorylation. P.D. Boyer and E.G. Kerbes, eds. (Academic Press, New York), Part A, Vol. 17, pp. 43-111.
2. CHO-CHUNG, Y.S. (1990). Perspectives in cancer research: Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy: New approaches to therapy. Cancer Res. 50, 7093-7100.
3. CHO-CHUNG, Y.S., CLAIR, T., TAGLIAFERRI, P., ALLY, S., KATSAROS, D., TORTORA, G., NECKERS, L., AVERY, T.L., CRABTREE, G.W., and ROBINS, R.K. (1989). Basic science review: Site-selective cyclic AMP analogs as new biological tools in growth control, differentiation and proto-oncogene regulation. Cancer Invest. 7, 161-177.
4. CHO-CHUNG, Y.S., CLAIR, T., TORTORA, G., and YOKOZAKI, H. (1991). Role of site-selective cAMP analogs in the control and reversal of malignancy. Pharmacol. Ther. 50, 1-33.
5. ZAMECNIK, P., and STEPHENSON, M. (1978). Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA 75, 280-284.